ASAnanya Saha

Ananya Saha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ananya Saha has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Upper respiratory tract CD8+ tissue-resident memory T cells protect against viral transmission

    by Sarah E. Michalets, Yixel Soto-Vazquez, Kathryn M. Moore, M. Elliott Williams, Ananya Saha, Ariana Jimenez, Yu-Shan Huang, Anice C. Lowen, Christopher D. Scharer, Alison Swaims-Kohlmeier, et al.

    Intranasal vaccination elicits CD8 tissue-resident memory T cells (TRM) throughout the respiratory tract that provide cross-protection against heterosubtypic viral strains and reduce immunopathology. We previously demonstrated that CD8 TRM can reduce the probability of respiratory virus transmission and the magnitude of infection, using a murine model of parainfluenza virus transmission. Here, we show that CD8 TRM-mediated protection occurs independently of circulating leukocytes, B cells, or CD4 T cells. Additionally, we investigate the contributions of CD8 TRM in different respiratory tract compartments and illustrate that CD8 TRM in the upper respiratory tract (URT), but not the lower respiratory tract (LRT), become activated and proliferate in response to transmitted virus. Furthermore, we demonstrate that CD8 TRM in the URT alone provide sufficient immune surveillance to prevent propagation of infection after viral transmission. These findings offer insights into the development of T cell–based respiratory virus vaccines and shed light on the critical role of URT CD8 TRM in the prevention of viral transmission.

  • Open Access

    Quantifying the role of pre-existing tissue resident cellular immunity in limiting respiratory virus transmission

    by Ananya Saha, Sarah E. Michalets, Ida Uddbäck, Hasan Ahmed, Jacob E. Kohlmeier, Rustom Antia, Katia Koelle

    Viral transmission from infected donors to uninfected recipients is the key event underlying the spread of viral pathogens at the level of a host population. Successful viral transmission from a donor to a recipient depends on several factors including the infectiousness of the donor. Donor infectiousness in turn can depend on the viral kinetics and viral load of the donor, donor behavior and symptoms, and donor immunity. Here, we use a mouse model of murine respirovirus (otherwise known as Sendai virus SeV) infection to quantitatively explore donor determinants of respiratory virus transmission. The experimental transmission studies we analyze are specifically designed to address the effect that pre-existing donor immunity may have on transmission potential by studying SeV transmission from both immunized and control (placebo-immunized) donors to naïve recipients. We specifically focus on the impact of tissue resident memory (TRM) CD8 T cells on donor transmission potential by considering immunization strategies that primarily generate CD8 T cell immunity. Through quantitative analyses of these experiments, we find that pre-existing CD8 TRMs act to reduce donor transmission potential. This finding is in agreement with previous findings and can be in part explained by a reduction in total infection load in immunized donors. However, even once differences in infection load between immunized and control donors are accounted for, immunized donors still have reduced infectiousness relative to control donors. We explore possible reasons for this unexpected pattern using a mathematical model that integrates within-host viral dynamics and between-host transmission occurrences. Analysis of model simulations, along with observations from knock-out experiments, suggests that interferon gamma (IFN- γ ) may be partly responsible for the observed differences in infectiousness between control and immune donors. Future experimental transmission studies should consider measuring IFN- γ levels and its effects when interpreting transmission outcomes in the context of host immunity.

  • Open Access

    Preventing Disease Emergence Following Eradication: Application to Mpox

    by Cora Hirst, Julia Deichmann, Ananya Saha, Ira Longini, Andreas Handel, Marc Lipsitch, Daniel Weissman, Rustom Antia

    We use simple mathematical models to explore the factors that influence the evolutionary emergence of mpox to a pathogen capable of sustained human to human transmission that poses a global threat. Smallpox eradication followed by the discontinuation of immunization with vaccinia has led to a decline in the level of population immunity against related poxviruses such as mpox. This decline in immunity results in an increase in both the number of spillovers and the extent of human to human transmission. We find that increases in transmissibility of mpox between humans have a much greater effect on the probability of evolutionary emergence compared with increases in the number of zoonotic spillovers. We suggest that while mpox only needs to have a reproductive number slightly greater than one to become endemic, subsequent adaptation is likely to further increase its transmissibility in the human population. As a consequence a much higher level of vaccination (or other intervention) is needed to control the pathogen after its evolutionary emergence compared with what is needed to prevent it from emerging in the first place.

  • Open Access

    Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

    by Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus, Judong Lee, Donald J. McGuire, Maria A. Cardenas, Pablo Umana, et al.

    (A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.

  • Open Access

    Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

    by Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus, Judong Lee, Donald J. McGuire, Maria A. Cardenas, Pablo Umana, et al.

    (A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.

  • Open Access

    Supplementary Figure S3 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

    by Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus, Judong Lee, Donald J. McGuire, Maria A. Cardenas, Pablo Umana, et al.

    (A-C) Relative frequency of stem-like (PD-1+TCF-1+TIM-3-) (A), transitory effector (PD-1+CX3CR1+TIM-3+) (B), and terminally differentiated (PD-1+CD101+TIM-3+) (C) Gp276+ and Gp33+ CD8 T cells in the spleen across treatment groups. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis the one-way ANOVA test was used. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.

  • Open Access

    Supplementary Figure S2 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

    by Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus, Judong Lee, Donald J. McGuire, Maria A. Cardenas, Pablo Umana, et al.

    (A) Design of the acute LCMV infection experiment. (B) Number of total CD8+ T cells, and of activated (CD44high) and naïve (CD44low) CD8+ T cells in the spleen of acutely infected mice after treatment in the two groups. (C) Representative FACS plots showing frequency of Gp33+ and Gp276+ CD8 T cells in the spleen across the two groups, quantified numbers are shown on the right. Data are representative of one out of 2 independent experiments of 3-5 mice per group. For statistical analysis the T-test was used; total numbers were Log10 transformed. Bars represent mean and SEM. Ns, non-significant; * p<0.05; ** p<0.01; *** p<0.001.

  • Open Access

    Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

    by Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus, Judong Lee, Donald J. McGuire, Maria A. Cardenas, Pablo Umana, et al.

    A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.

  • Open Access

    Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

    by Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus, Judong Lee, Donald J. McGuire, Maria A. Cardenas, Pablo Umana, et al.

    A) Number of total lymphocytes and of CD8+ T cells in the spleen of mice treated with either concomitant or sequential combination of CT and aPD-L1. (B) Representative FACS plots showing the frequency of stem-like (PD-1+TCF-1+TIM-3-), effector transitory (PD-1+CX3CR1+TIM-3+) and terminally differentiated (PD-1+CD101+TIM-3+) Gp33+ CD8 T cells in the spleen across the treatment groups, with quantified numbers shown in (C). Data are pooled from 2 independent experiments of 4-6 mice per group. For statistical analysis the T-test was used, total numbers were Log10 transformed. Bars represent mean and SEM. * p<0.05; ** p<0.01; **** p<0.0001.

  • Open Access

    Supplementary Figure S1 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

    by Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel T. McManus, Judong Lee, Donald J. McGuire, Maria A. Cardenas, Pablo Umana, et al.

    (A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.